Clinical Neuroscience of Addiction: Similarities and Differences Between Alcohol and Other Drugs

Alcoholism: Clinical and Experimental Research

Volumn 39, Issue 11, 2015, Pages 2073-2084

  Karoly, Hollis C ^a   Yorkwilliams, Sophie L ^a   Hutchison, Kent E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Alcohol; Medications; Neuroimaging; Neuroinflammation

Indexed keywords

DRUGS USED IN THE TREATMENT OF ADDICTION;

ALCOHOL USE DISORDER; ALCOHOLISM; CONNECTOME; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; REWARD; SUBSTANCE ABUSE; TREATMENT OUTCOME; ALCOHOL-RELATED DISORDERS; ANIMAL; BEHAVIOR, ADDICTIVE; DRUG USE; METABOLISM; NERVE CELL NETWORK; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

ALCOHOL-RELATED DISORDERS; ANIMALS; BEHAVIOR, ADDICTIVE; DRUG USERS; HUMANS; NERVE NET; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 84945276882     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12884     Document Type: Review

References (171)

1. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M (2013) Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2:1-70.
2. Anthenelli RM, Blom TJ, McElroy SL, Keck PE (2008) Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 103:687-694.
3. Anton RF, Myrick H, Baros AM, Latham PK, Randall PK, Wright TM, Stewart SH, Waid R, Malcolm R (2009) Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol 29:334-342.
4. Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, Randall PK (2011) Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 168:709-717.
5. Asensio S, Romero MJ, Palau C, Sanchez A, Senabre I, Morales JL, Carcelen R, Romero FJ (2010) Altered neural response of the appetitive emotional system in cocaine addiction: an fMRI Study. Addict Biol 15:504-516.
6. Baler RD, Volkow ND (2006) Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med 12:559-566.
7. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG (2008) Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 103:2035-2044.
8. Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E (2014) Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. Alcohol Clin Exp Res 38:2169-2177.
9. Beardsley PM, Hauser KF (2014) Glial modulators as potential treatments of psychostimulant abuse. Adv Pharmacol 69:1-69.
10. Berger SP, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, Montgomery MA, Goldsmith RJ, Bloch DA, Singal BM (2005) A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 100:58-67.
11. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, Nunes EV (2006) A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 81:267-274.
12. Blanco AM, Vallés SL, Pascual M, Guerri C (2005) Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. J Immunol 175:6893-6899.
13. Blodgett JC, Del Re AC, Maisel NC, Finney JW (2014) A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 38:1481-1488.
14. Blum K, Gardner E, Oscar-Berman M, Gold M (2012) "Liking" and "wanting" linked to reward deficiency syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. Curr Pharm Des 18:113-118.
15. Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL, Kurian V, Ernst M, London ED (2002) Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 26:376-386.
16. Bouhnik A-D, Chesney M, Carrieri P, Gallais H, Moreau J, Moatti J-P, Obadia Y, Spire B (2002) Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr 31:S149-S153.
17. Bozarth MA (1986) Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system. Behav Brain Res 22:107-116.
18. Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA (2008) A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 32:1429-1438.
19. Cahill K, Stead LF, Lancaster T, Polonio IB (2012) Nicotine receptor partial agonists for smoking cessation. Sao Paulo Med J 130:346-347.
20. Cameron DL, Williams JT (1994) Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J Neurosci 14:6763-6767.
21. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP (1999) Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156:11-18.
22. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB (2005) Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477.
23. Coller JK, Hutchinson MR (2012) Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther 134:219-245.
24. Collins FS (2011) Reengineering translational science: the time is right. Sci Transl Med 3:90cm17.
25. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor R, Fry-Smith A, Day E, Lintzeris N, Roberts T (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11:1-171.
26. Courtney KE, Ghahremani DG, Ray LA (2013) Fronto-striatal functional connectivity during response inhibition in alcohol dependence. Addict Biol 18:593-604.
27. Covey LS, Glassman AH, Stetner F (1999) Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 18:31-40.
28. Crews FT, Nixon K (2009) Mechanisms of neurodegeneration and regeneration in alcoholism. Alcohol Alcohol 44:115-127.
29. Cui C, Shurtleff D, Harris RA (2013) Neuroimmune mechanisms of alcohol and drug addiction. Int Rev Neurobiol 118:1-12.
30. Daglish MR, Weinstein A, Malizia AL, Wilson S, Melichar JK, Lingford-Hughes A, Myles JS, Grasby P, Nutt DJ (2003) Functional connectivity analysis of the neural circuits of opiate craving:"more" rather than "different"? NeuroImage 20:1964-1970.
31. Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, Neve RL, Nestler EJ, Carlezon WA Jr (2009) Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci 29:1855-1859.
32. D'Souza MS, Markou A (2011) Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract 6:4-16.
33. Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F (2012) Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 107:1297-1306.
34. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D (2008) Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33:1162-1170.
35. Ersche KD, Williams GB, Robbins TW, Bullmore ET (2013) Meta-analysis of structural brain abnormalities associated with stimulant drug dependence and neuroimaging of addiction vulnerability and resilience. Curr Opin Neurobiol 23:615-624.
36. Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481-1489.
37. Fields HL, Margolis EB (2015) Understanding opioid reward. Trends Neurosci 38:217-225.
38. Fiore M, Jaen CR, Baker T, Bailey W, Benowitz N, Curry S, Dorfman S, Froelicher E, Goldstein M, Healton C (2008) Treating tobacco use and dependence: 2008 update. Respir Care 53:1217-1222.
39. Flórez G, García-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J (2008) Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 32:1251-1259.
40. Fox HC, D'Sa C, Kimmerling A, Siedlarz KM, Tuit KL, Stowe R, Sinha R (2012) Immune system inflammation in cocaine dependent individuals: implications for medications development. Hum Psychopharmacol 27:156-166.
41. Franklin TR, Wang Z, Wang J, Sciortino N, Harper D, Li Y, Ehrman R, Kampman K, O'Brien CP, Detre JA, Childress AR (2007) Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology 32:2301-2309.
42. Fu L-P, Bi G-H, Zou Z-T, Wang Y, Ye E-M, Ma L, Yang Z (2008) Impaired response inhibition function in abstinent heroin dependents: an fMRI study. Neurosci Lett 438:322-326.
43. Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68:1691-1700.
44. Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV (2014) Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 109:1274-1284.
45. Garrison GD, Dugan SE (2009) Varenicline: a first-line treatment option for smoking cessation. Clin Ther 31:463-491.
46. Gilpin NW, Koob GF (2008) Neurobiology of alcohol dependence: focus on motivational mechanisms. Alcohol Res Health 31:185-195.
47. Goldstein RZ, Volkow ND (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12:652-669.
48. Gonzales R, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18:10663-10671.
49. Gonzalez A, Mimiaga MJ, Israel J, Bedoya CA, Safren SA (2013) Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav 17:168-173.
50. González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR (2007) Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 87:1-9.
51. Goudriaan AE, De Ruiter MB, Van Den Brink W, Oosterlaan J, Veltman DJ (2010) Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study. Addict Biol 15:491-503.
52. Greutman MD, Gales MA, Gales BJ (2015) Gabapentin in alcohol dependence. J Pharm Technol 31:177-183.
53. Grusser SM, Wrase J, Klein S, Hermann D, Smolka MN, Ruf M, Weber-Fahr W, Flor H, Mann K, Braus DF, Heinz A (2004) Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology 175:296-302.
54. Hart CL, Haney M, Collins ED, Rubin E, Foltin RW (2007a) Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses. Drug Alcohol Depend 86:274-277.
55. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW (2007b) Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. Behav Pharmacol 18:71-75.
56. Hart CL, Ward AS, Collins ED, Haney M, Foltin RW (2004) Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug Alcohol Depend 73:279-287.
57. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T (2013) Efficacy of interventions to combat tobacco addiction: Cochrane update of 2012 reviews. Addiction 108:1711-1721.
58. He J, Crews FT (2008) Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol 210:349-358.
59. Hendrickson LM, Zhao-Shea R, Pang X, Gardner PD, Tapper AR (2010) Activation of α4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci 30:10169-10176.
60. Herz A (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology 129:99-111.
61. Hester R, Garavan H (2004) Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci 24:11017-11022.
62. Holmes A, Spanagel R, Krystal JH (2013) Glutamatergic targets for new alcohol medications. Psychopharmacology 229:539-554.
63. Hutchinson MR, Northcutt A, Hiranita T, Wang X, Lewis S, Thomas J, van Steeg K, Kopajtic T, Loram L, Sfregola C (2012) Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 32:11187-11200.
64. Hyman SE (1996) Addiction to cocaine and amphetamine. Neuron 16:901-904.
65. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J (2008) Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165:1442-1448.
66. Jayaram-Lindström N, Wennberg P, Beck O, Franck J (2005) An open clinical trial of naltrexone for amphetamine dependence: compliance and tolerability. Nord J Psychiatry 59:167-171.
67. Johnson BA (2004) Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother 4:751-758.
68. Johnson BA, Ait-Daoud N (2010) Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 16:2103-2112.
69. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA (2005) Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 165:1600-1605.
70. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61:905-912.
71. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-1685.
72. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, Liu L (2013) Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 70:1338-1346.
73. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang X-Q (2007a) Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol 10:85-98.
74. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (2007b) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641-1651.
75. Johnson SW, North RA (1992) Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol 450:455-468.
76. Kamarajan C, Porjesz B, Jones KA, Choi K, Chorlian DB, Padmanabhapillai A, Rangaswamy M, Stimus AT, Begleiter H (2005) Alcoholism is a disinhibitory disorder: neurophysiological evidence from a Go/No-Go task. Biol Psychol 69:353-373.
77. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP (2004) A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 75:233-240.
78. Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O'Brien CP (2013) A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 133:94-99.
79. Karoly HC, Harlaar N, Hutchison KE (2013) Substance use disorders: a theory-driven approach to the integration of genetics and neuroimaging. Ann N Y Acad Sci 1282:71-91.
80. Khazaal Y, Cornuz J, Bilancioni R, Zullino DF (2006) Topiramate for smoking cessation. Psychiatry Clin Neurosci 60:384-388.
81. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, Matthews AK, Stachoviak RJ (2012) Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol 32:630-636.
82. King AC, Meyer PJ (2000) Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66:563-572.
83. Komanduri R (2003) Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry 64:612.
84. Koob GF (2000) Neurobiology of addiction: toward the development of new therapies. Ann N Y Acad Sci 909:170-185.
85. Koob GF (2004) A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol 68:1515-1525.
86. Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238.
87. Kraemer KL (2014) Review: in alcohol use disorders, oral naltrexone, 50 mg/d, or acamprosate reduces return to drinking. Ann Intern Med 161:JC7.
88. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM (2014) Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445-452.
89. Kreek MJ (2000) Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186-216.
90. Kresina TF, Eldred L, Bruce RD, Francis H (2005) Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. AIDS 19:S221-S226.
91. Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH (2007) Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 31:604-611.
92. Krystal JH, Petrakis IL, Krupitsky E, Schütz C, Trevisan L, D'Souza DC (2003) NMDA receptor antagonism and the ethanol intoxication signal. Ann N Y Acad Sci 1003:176-184.
93. Li Q, Wang Y, Zhang Y, Li W, Zhu J, Zheng Y, Chen J, Zhao L, Zhou Z, Liu Y (2013) Assessing cue-induced brain response as a function of abstinence duration in heroin-dependent individuals: an event-related fMRI study. PLoS One 8:e62911.
94. Lile JA, Kelly T, Hays L (2014) Separate and combined effects of gabapentin and Δ9-THC doses in cannabis users discriminating Δ9-THC. Drug Alcohol Depend 140:e123.
95. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R; NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group. (2013) A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med 7:277-286.
96. Liu H, Hao Y, Kaneko Y, Ouyang X, Zhang Y, Xu L, Xue Z, Liu Z (2009) Frontal and cingulate gray matter volume reduction in heroin dependence: optimized voxel-based morphometry. Psychiatry Clin Neurosci 63:563-568.
97. Luo Y-X, Xue Y-X, Shen H-W, Lu L (2013) Role of amygdala in drug memory. Neurobiol Learn Mem 105:159-173.
98. Margolin A, Kosten TR, Avants SK, Wilkins J, Ling W, Beckson M, Arndt IO, Cornish J, Ascher JA, Li SH, Bridge P (1995) A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 40:125-131.
99. Martinotti G, Di Nicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, Aliotta F, Romanelli R, Verrastro V, Petruccelli F (2014) Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol 34:709-715.
100. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37:1689-1698.
101. Mason BJ, Light JM, Williams LD, Drobes DJ (2009) Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol 14:73-83.
102. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174:70-77.
103. Mattick RP, Breen C, Kimber J, Davoli M (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev (3):Art. No.: CD002209. doi: 10.1002/14651858.CD002209.pub2.
104. Mattick RP, Breen C, Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2:1-87.
105. Mayfield J, Ferguson L, Harris RA (2013) Neuroimmune signaling: a key component of alcohol abuse. Curr Opin Neurobiol 23:513-520.
106. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E (2009) Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 66:185-190.
107. Merikangas KR, McClair VL (2012) Epidemiology of substance use disorders. Hum Genet 131:779-789.
108. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489-497.
109. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL (2012) Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 223:299-306.
110. Monterosso JR, Aron AR, Cordova X, Xu J, London ED (2005) Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend 79:273-277.
111. Motzkin JC, Baskin-Sommers A, Newman JP, Kiehl KA, Koenigs M (2014) Neural correlates of substance abuse: reduced functional connectivity between areas underlying reward and cognitive control. Hum Brain Mapp 35:4282-4292.
112. Myrick H, Henderson S, Brady KT, Malcolm R (2001) Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry 62:19-23.
113. Nestler EJ (2001a) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2:119-128.
114. Nestler EJ (2001b) Molecular neurobiology of addiction. Am J Addict 10:201-217.
115. Nestler EJ (2013) Cellular basis of memory for addiction. Dialogues Clin Neurosci 15:431-443.
116. Nie Z, Yuan X, Madamba SG, Siggins GR (1993) Ethanol decreases glutamatergic synaptic transmission in rat nucleus accumbens in vitro: naloxone reversal. J Pharmacol Exp Ther 266:1705-1712.
117. Norden DM, Godbout JP (2013) Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 39:19-34.
118. Northcutt AL, Hutchinson MR, Wang X, Baratta MV, Hiranita T, Cochran TA, Pomrenze MB, Galer EL, Kopajtic TA, Li CM, Amat J, Larson G, Cooper DC, Huang Y, O'Neill CE, Yin H, Zahniser NR, Katz JL, Rice KC, Maier SF, Bachtell RK, Watkins LR (2015) DAT isn't all that: cocaine reward and reinforcement require toll-like receptor 4 signaling. Mol Psychiatry doi: 10.1038/mp.2014.177 [Epub ahead of print].
119. NOT-AA-14-009 (2014) Notice to clarify the scope for PA-13-161 alcohol use disorders: treatment, services, and recovery research (R03). April 24. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-AA-14-009.html. Accessed March 2, 2015.
120. Nuijten M, Blanken P, van den Brink W, Hendriks V (2014) Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in the Netherlands. Drug Alcohol Depend 138:177-184.
121. Nutt DJ (2014) The role of the opioid system in alcohol dependence. J Psychopharmacol 28:8-22.
122. O'Brien CP (1984) Use of naltrexone to extinguish opioid-conditioned responses. J Clin Psychiatry 45:53-56.
123. O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R (2006) A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 166:667-674.
124. Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR (2014) Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res 16:288-296.
125. Ortiz J, Fitzgerald LW, Charlton M, Lane S, Trevisan L, Guitart X, Shoemaker W, Duman RS, Nestler EJ (1995) Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 21:289-298.
126. Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I (2011) Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry 11:41.
127. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6:193-201.
128. Plebani JG, Lynch KG, Yu Q, Pettinati HM, O'Brien CP, Kampman KM (2012) Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend 121:163-166.
129. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR (2006) Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 63:219-228.
130. Qin L, Crews FT (2012) NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration. J Neuroinflammation 9:5.
131. Raby WN, Coomaraswamy S (2004) Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry 65:84-86.
132. Rassnick S, Pulvirenti L, Koob GF (1992) Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology 109:92-98.
133. Ray LA, Courtney KE, Hutchison KE, MacKillop J, Galvan A, Ghahremani DG (2014) Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues. Alcohol Clin Exp Res 38:78-89.
134. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 264:2511-2518.
135. Reid MS, Palamar J, Raghavan S, Flammino F (2007) Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology 192:147-158.
136. Reis AD, Castro LA, Faria R, Laranjeira R (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30:132-135.
137. Richmond R, Zwar N (2003) Review of bupropion for smoking cessation. Drug Alcohol Rev 22:203-220.
138. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F (2004) Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37:37-40.
139. Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, Lerman C (2005) Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180:41-48.
140. Rustembegovic A, Sofic E, Kroyer G (2001) A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh 56:211-212.
141. Schacht JP, Anton RF, Myrick H (2013) Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol 18:121-133.
142. Schmitz JM, Stotts AL, Rhoades HM, Grabowski J (2001) Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 26:167-180.
143. Shinn AK, Greenfield SF (2010) Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 71:634-648.
144. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Kao UH, Wang P-C, Bholat MA, Ling W (2008) Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis 27:13-23.
145. Sofuoglu M, Poling J, Mouratidis M, Kosten T (2006) Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology 184:645-651.
146. Sood A, Ebbert JO, Schroeder DR, Croghan IT, Sood R, Vander Weg MW, Wong GY, Hays JT (2007) Gabapentin for smoking cessation: a preliminary investigation of efficacy. Nicotine Tob Res 9:291-298.
147. Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, Hays JT (2010) Gabapentin for smoking cessation. Nicotine Tob Res 12:300-304.
148. Staines GL, Magura S, Foote J, Deluca A, Kosanke N (2001) Polysubstance use among alcoholics. J Addict Dis 20:57-73.
149. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T (2012) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 11:1-267.
150. Stewart J, de Wit H, Eikelboom R (1984) Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. Psychol Rev 91:251-268.
151. Sullivan L, Moore B, Chawarski M, Schottenfeld R, O'Connor P, Fiellin D (2005) Buprenorphine reduces HIV risk behavior among opioid dependent patients in primary care. J Gen Intern Med 20:172.
152. Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433.
153. Taylor CP, Gee NS, Su T-Z, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29:233-249.
154. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ (1991) A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 548:100-110.
155. Ting-A-Kee R, van der Kooy D (2012) The neurobiology of opiate motivation. Cold Spring Harb Perspect Med 2. pii: a012096.
156. Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O'Malley SS (2010) Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend 111:200-206.
157. Trevisan LA, Ralevski E, Keegan K, Oville A, Vuppalapati D, Gonzalez G, Limoncelli D, Petrakis IL (2008) Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients. Addict Disord Their Treat 7:119-128.
158. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, Strain EC, Bigelow GE (2014) Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend 140:92-100.
159. Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE (1996) Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 279:524-538.
160. Watkins LR, Hutchinson MR, Rice KC, Maier SF (2009) The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30:581-591.
161. Weiland BJ, Sabbineni A, Calhoun VD, Welsh RC, Bryan AD, Jung RE, Mayer AR, Hutchison KE (2014) Reduced left executive control network functional connectivity is associated with alcohol use disorders. Alcohol Clin Exp Res 38:2445-2453.
162. Weir SJ, DeGennaro LJ, Austin CP (2012) Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res 72:1055-1058.
163. White HS, Brown SD, Woodhead J, Skeen GA, Wolf HH (2000) Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41:17-20.
164. White WD, Crockford D, el-Guebaly N, Patten S (2005) A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 7:809-813.
165. Wise RA (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319-340.
166. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD (1999) A randomized trial of naltrexone for smoking cessation. Addiction 94:1227-1237.
167. Wrase J, Makris N, Braus DF, Mann K, Smolka MN, Kennedy DN, Caviness VS, Hodge SM, Tang L, Albaugh M (2008) Amygdala volume associated with alcohol abuse relapse and craving. Am J Psychiatry 165:1179-1184.
168. Xi Z-X, Ramamoorthy S, Shen H, Lake R, Samuvel DJ, Kalivas PW (2003) GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine. J Neurosci 23:3498-3505.
169. Yamamoto BK, Raudensky J (2008) The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 3:203-217.
170. Zullino DF, Cottier AC, Besson J (2002) Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 26:1221-1223.
171. Zullino DF, Krenz S, Zimmermann G, Miozzari A, Rajeswaran R, Kolly S, Khazaal Y (2005) Topiramate in opiate withdrawal-comparison with clonidine and with carbamazepine/mianserin. Subst Abuse 25:27-33.